CinnaTropin®


(Somatropin)

Expand Your Child’s Happiness


Description

CinnaTropin® is a polypeptide hormone of recombinant DNA origin. The hormone is synthesized by a special strain of E.coli bacteria that has been modified by the addition of a plasmid which carries the gene for human growth hormone. CinnaTropin® contains the identical sequence of 191 amino acids constituting the naturally occurring pituitary human growth hormone with a molecular weight of about 22,000 Daltons.

CinnaTropin® is supplied as a sterile solution for subcutaneous injection in ready-to-administer prefilled pens with a volume of 1.5 mL.

Each CinnaTropin® contains the following (see Table 1):

Component

5 mg/1.5 mL

Somatropin

5 mg

Histidine

1 mg

Poloxamer 188

4.5 mg

Phenol

4.5 mg

Mannitol

60 mg

HCl/NaOH

as needed

Water for Injection

up to 1.5 mL

Overview

CinnaTropin® (Somatropin) is recombinant human growth hormone which has remarkable role for the growth of bones and muscles.

CinnaTropin® (Somatropin) is prescribed for children and adults who do not have efficient physiologic growth hormone; it treats their growth failure. People with chronic kidney failure, Noonan syndrome, Turner syndrome, Prader-Willi syndrome, short stature at birth with no catch-up growth, and other causes would get benefit from this medicine. CinnaTropin® (Somatropin) is also used to prevent severe weight loss in people with AIDS, or to treat short bowel syndrome.

CinnaTropin® (Somatropin) may also be prescribed for other reasons not listed in this website.

Indication and Usage

Pediatric Patients

CinnaTropin® (somatropin [rDNA origin] injection) is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone (GH).

CinnaTropin® [somatropin (rDNA origin) injection] is indicated for the treatment of pediatric patients who have growth failure due to Prader-Willi Syndrome (PWS). The diagnosis of PWS should be confirmed by appropriate genetic testing [see Contraindications and Warnings and Precautions].

CinnaTropin® [somatropin (rDNA origin) injection] is indicated for the treatment of growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 years.

CinnaTropin® [somatropin (rDNA origin) injection] is indicated for the treatment of growth failure associated with Turner syndrome.

CinnaTropin®  (somatropin [rDNA origin] injection) is indicated for the treatment of idiopathic short stature (ISS), also called non-growth hormone-deficient short stature, defined by height standard deviation score (SDS) ≤ -2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.

Adult Patients

CinnaTropin® (somatropin [rDNA origin] injection) is indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD) who meet either of the following two criteria:

  • Adult Onset (AO): Patients who have GHD, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
  • Childhood Onset (CO): Patients who were GH deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.

Patients who were treated with somatropin for growth hormone deficiency in childhood and whose epiphyses are closed should be reevaluated before continuation of somatropin therapy at the reduced dose level recommended for growth hormone deficient adults. Confirmation of the diagnosis of adult growth hormone deficiency in both groups involves an appropriate growth hormone provocative test with two exceptions: (1) patients with multiple other pituitary hormone deficiencies due to organic disease; and (2) patients with congenital/genetic growth hormone deficiency.

FAQs

A

CinnaTropin® should be administered subcutaneously at a 90° angle. The best areas for administration of CinnaTropin® are:

  • Upper arms (on the side or back, at least 7.5 cm below the shoulders and above the elbows).
  • Front of the thighs (at least 7.5 cm below the hip and above the knees).
  • Belly (below the ribs and above the hip bone, at least 5 cm away from the belly button).
A

The secretion of endogenous growth hormone occurs at night, 2-3 hours after the onset of sleep. It is better to use CinnaTropin® at night and before bed in order to simulate the natural cycle of the hormone.

A

The secretion of endogenous growth hormone occurs at night, 2-3 hours after the onset of sleep. It is better to use CinnaTropin® at night and before bed in order to simulate the natural cycle of the hormone.

A

After the initial injection, each pen can be stored for up to 3 weeks at below the room temperature (<25°C).

more